Clinical study of PD-L1 antibody ASC22 for cure of HIV completes first patient dosing
Shanghai Public Health Clinical Center Completed the First Patient Dosing in Clinical Study of PD-L1 Antibody ASC22 in Combination with Chidamide for Functional Cure of HIV Infection